Choreo LLC Trims Position in ICU Medical, Inc. (NASDAQ:ICUI)

Choreo LLC decreased its holdings in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 25.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,653 shares of the medical instruments supplier’s stock after selling 906 shares during the period. Choreo LLC’s holdings in ICU Medical were worth $409,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in ICUI. Allworth Financial LP lifted its position in ICU Medical by 100.0% during the 3rd quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 100 shares during the period. Venturi Wealth Management LLC lifted its holdings in shares of ICU Medical by 1,510.0% during the third quarter. Venturi Wealth Management LLC now owns 322 shares of the medical instruments supplier’s stock worth $59,000 after purchasing an additional 302 shares during the period. Point72 Hong Kong Ltd purchased a new position in ICU Medical in the 3rd quarter valued at $72,000. Greenleaf Trust purchased a new position in ICU Medical in the 3rd quarter valued at $207,000. Finally, OLD National Bancorp IN purchased a new position in ICU Medical during the 3rd quarter worth $218,000. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical Price Performance

ICUI stock opened at $156.94 on Thursday. The firm has a 50 day moving average of $160.73 and a 200-day moving average of $164.16. The company has a market cap of $3.84 billion, a price-to-earnings ratio of -34.34 and a beta of 0.63. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. ICU Medical, Inc. has a 12-month low of $93.36 and a 12-month high of $196.26.

Insider Activity at ICU Medical

In other news, CEO Vivek Jain sold 12,000 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $162.91, for a total transaction of $1,954,920.00. Following the completion of the transaction, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at $17,039,245.63. This trade represents a 10.29 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director David C. Greenberg sold 972 shares of the company’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $158.11, for a total value of $153,682.92. Following the completion of the sale, the director now directly owns 5,037 shares in the company, valued at approximately $796,400.07. The trade was a 16.18 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 17,737 shares of company stock valued at $2,879,752 in the last ninety days. Corporate insiders own 6.70% of the company’s stock.

Analyst Ratings Changes

ICUI has been the topic of several analyst reports. Jefferies Financial Group raised shares of ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 target price on the stock in a report on Wednesday, December 11th. Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. StockNews.com raised ICU Medical from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, KeyCorp lifted their price target on ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a research note on Wednesday, November 13th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $199.67.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.